Copenhagen, Denmark, December 21, 2015 – – Vipergen ApS, a biotechnology company focused on small molecule drug discovery using its proprietary 2 nd generation DNA-encoded library platform, today announced the initiation of a drug discovery collaboration with Actelion Pharmaceuticals Ltd (a subsidiary of Actelion Ltd, SIX: ATLN), a leading biopharmaceutical company focused on the discovery, development and commercialization of innovative drugs for diseases with significant unmet medical needs.
Under the terms of the agreement, Vipergen is applying its small molecule discovery engine, which leverages a high fidelity proprietary DNA-encoded library platform to identify novel hits/leads for selected targets from Actelion. Actelion obtains exclusive options to selected hits and hit series. The therapeutic area of the targets was not disclosed. No information about the financial arrangement was provided.
About Actelion Ltd
Actelion Ltd. is a leading biopharmaceutical company focused on the discovery, development and commercialization of innovative drugs for diseases with significant unmet medical needs.
Actelion is a leader in the field of pulmonary arterial hypertension (PAH). Our portfolio of PAH treatments covers the spectrum of disease, from WHO Functional Class (FC) II through to FC IV, with oral, inhaled and intravenous medications. Although not available in all countries, Actelion has treatments approved by health authorities for a number of specialist diseases including Type 1 Gaucher disease, Niemann-Pick type C disease, Digital Ulcers in patients suffering from systemic sclerosis, and mycosis fungoides type cutaneous T-cell lymphoma.
Founded in late 1997, with now over 2,400 dedicated professionals covering all key markets around the world including Europe, the US, Japan, China, Russia and Mexico, Actelion has its corporate headquarters in Allschwil / Basel, Switzerland. Actelion shares are traded on the SIX Swiss Exchange (ticker symbol: ATLN) as part of the Swiss blue-chip index SMI (Swiss Market Index SMI®). All trademarks are legally protected.
About Vipergen ApS
Vipergen is dedicated to small molecule drug discovery using DNA-encoded library platforms.
Vipergen seeks to leverage its innovative and proprietary drug discovery platforms in partnerships with pharmaceutical and biotech companies.
Vipergen´s two 2 nd generation technology platforms – The YoctoReactor® for synthesizing DNAencoded chemical libraries and Binder Trap Enrichment®
for screening of such libraries – are designed to deliver high fidelity drug discovery.
For further details about Vipergen and the YoctoReactor®/ Binder Trap Enrichment® drug discovery technology platforms please visit www.vipergen.com or contact
Vipergen ApS
Dr. Nils Hansen, Chief Executive Officer
Phone: +45 2523 6680
[email protected]